Meta‐analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma

作者：Y. Li, Yu Fan, Shiyu Cao, Yu‐fei Zhang, J.P. Li · 发表于：International Journal of Gynecology & Obstetrics · 年份：2025 · DOI：10.1002/ijgo.16157 · 被引用次数：5 · 研究领域：Endometrial and Cervical Cancer Treatments、Cancer Genomics and Diagnostics、Cervical Cancer and HPV Research

BACKGROUND: In 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups. OBJECTIVE: To compare survival of endometrial carcinoma patients with different mutational profiles. SEARCH STRATEGY: Studies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases. SELECTION CRITERIA: We included relevant studies based on the literature type, data integrity and the methodological quality. DATA COLLECTION AND ANALYSIS: statistic. MAIN RESULTS: Data were meta-analyzed from nine studies involving 4755 patients, who were classified into the following mutational profiles: p53abn, 745 patients (15.6%); MMRd, 1454 patients (30.6%); POLEmut, 351 patients (7.4%); and p53wt, 2205 patients (46.4%). Compared to the p53wt group, the p53abn group showed significantly worse overall survival (OS) (HR 2.31, 95% CI: 1.67-3.19), progression-free survival (PFS) (HR 2.86, 95% CI: 1.45-5.64) and disease-specific survival (HR 2.60, 95% CI: 1.41-4.79); and the MMRd group showed significantly worse OS (HR 1.30, 95% CI: 1.11-1.53) and PFS (HR 1.27, 95% CI: 1.01-1.59). The POLEmut group, in contrast, showed similar survival as the p53wt group. CONCLUSIONS: The four mutational profiles for patients with endometrial carcinoma in the Cancer Genome Atlas for Endometrial Cancer are associated with worse to better survival in the trend: p53abn < MMRd < POLEmut ≈ p53wt...